A landmark Phase 2 study will test smoked, high-THC flower versus placebo in 320 veteran participants with moderate to severe PTSD. Here’s what’s being studied and why it matters for DMV patients.

A bipartisan House bill would require the U.S. Department of Veterans Affairs to examine medical marijuana for PTSD and chronic pain—starting with an observational study.

Congress’s PATH Caucus outlines a federal–state roadmap to integrate psychedelic-assisted therapy into U.S. care with clinical safeguards, data tracking and provider standards.

Marijuana Moment reports a Texas Senate candidate’s alcohol-linked cash haul while opposing cannabis reform—plus new research on teen use and clinical science DMVers should track.

State health officials pulled back proposed fee increases for Oregon’s supervised psilocybin program after broad backlash, but funding questions and possible tax changes remain.

Psychedelic Alpha reports that Resilient has resubmitted its MDMA-for-PTSD application two years after a prior rejection. Here’s what to watch, timelines, and DMV impacts.

A power shift at Lykos Therapeutics could revive MDMA-assisted therapy—and Rick Doblin’s influence. Here’s what’s changing, why it matters, and how DMV residents should watch the next moves.

A new nonprofit, After The Story, will fund legal psychedelic-assisted care and integration for reporters and media workers carrying trauma from the job.

New research suggests festivals and ceremonial settings may nurture similar trauma relief through community and shared meaning—raising practical lessons for DMV readers.

Psychedelic Alpha reports that two psychiatrists in New Zealand have been cleared to prescribe MDMA for PTSD. Here’s what happened and what DMV readers should know.

Resilient resubmits MDMA-assisted therapy to FDA, Definium reports positive oral LSD Phase 3 data in GAD, and Canada funds a C$24M cannabis–brain health consortium.